| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5843853 | Pharmacological Research | 2011 | 4 Pages |
Abstract
Paediatric cardiomyopathy and heart failure are distinct but frequently associated conditions, which have a high mortality. Traditional medical therapy has evolved to incorporate newer classes of heart failure drugs, although the evidence to support efficacy in children is limited. This perspective article discusses the rationale, benefits and limitations of the various classes of drug therapy used in paediatric heart failure due to cardiomyopathy or congenital heart disease. Controversies in management and challenges for future development are highlighted.
Graphical abstractDownload high-res image (127KB)Download full-size image
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Kathryn Timberlake, Paul F. Kantor,